Last reviewed · How we verify
DVS-233 SR
DVS-233 SR is a sustained-release formulation of venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic levels of serotonin and norepinephrine by blocking their reuptake.
DVS-233 SR is a sustained-release formulation of venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic levels of serotonin and norepinephrine by blocking their reuptake. Used for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder.
At a glance
| Generic name | DVS-233 SR |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Target | Serotonin transporter (SERT), Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | Phase 3 |
Mechanism of action
Venlafaxine works by inhibiting the reuptake of both serotonin and norepinephrine at the presynaptic neuron, thereby increasing their concentration in the synaptic cleft. The SR (sustained-release) formulation provides prolonged drug delivery, allowing for once-daily dosing and more stable plasma concentrations compared to immediate-release formulations. This mechanism is thought to restore neurotransmitter balance in mood disorders.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Social anxiety disorder
- Panic disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Sexual dysfunction
- Sweating
- Hypertension
Key clinical trials
- Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD) (PHASE3)
- Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR) (PHASE1)
- Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects (PHASE4)
- Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder (PHASE3)
- Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder (PHASE3)
- Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder (PHASE3)
- Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder (PHASE3)
- Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |